Affibody and Agilent Technologies to Develop Robust Protein Sample
Affibody AB and Agilent Technologies Inc. announced a cooperative agreement to develop advanced protein sample preparation solutions for human biomarker discovery. Affibody will design and develop engineered Affibody® ligands for specific protein targets designated by Agilent, which Agilent plans to use to expand its line of proteomic sample preparation products. At the end of the development phase of the agreement, Affibody will supply Agilent with production quantities of the materials.
Under the agreement, Affibody will deliver highly specific and robust affinity capture ligands that will enable Agilent to expand its market-leading Multiple Affinity Removal System technology with new product configurations. These products will enable scientists involved in biomarker discovery from human serum/plasma to continue to dig deeper into the serum proteome, in order to discover and identify potential biomarkers that can be used for human disease diagnosis, monitoring of therapeutic intervention, and prognosis. The robustness of the Affibody® ligand permits unsurpassed reproducibility for sample-to-sample comparison, resulting in greater certainty and clarity of scientific data.
Other news from the department business & finance
